Randomised controlled trials are the gold standard of evidence to support causal conclusions on the benefits and risks of medicines in regulatory decision making along the lifecycle.
However, in some situations, causal conclusions may be derived from a setting where the investigational medicinal product data was collected under a clinical trial protocol while the control arm was not a randomized arm in that same protocol. In these situations, a so-called external control, may be derived from data from other clinical trials, real-world data (RWD) or other data sources.
A reflection paper shall be drafted to describe the main challenges with external controls and further discuss the circumstances and methodological constraints under which the use of external controls could be considered appropriate for generating pivotal or supportive evidence, either for efficacy, safety or other relevant regulatory decision-making objectives.
This concept paper outlines the scope and content of the reflection paper.
Keywords: Clinical trial design, external controls, regulatory decision-making